公开(公告)号：US20150183862A1

公开(公告)日：2015-07-02

申请号：US14582631

申请日：2014-12-24

Applicant: Vanderbilt University ,  Vanderbilt University

Inventor： James R. EDWARDS ,  Gregory R. MUNDY

IPC: C07K16/24

CPC classification number: C07K16/24 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/22 ,  C07K2317/76

Abstract: The invention regards the modulation of TGF-β activity by administering to a subject an antibody that binds to TGF-β, thereby increasing bone growth, bone formation, bone mass and bone strength. The antibody acts to increase osteoblast number and function while at the same time decreasing osteoclast number and function. Such drugs are useful in the treatment of diseases or disorders such as osteoporosis, Paget's disease, metastatic bone cancer, myeloma bone disease, bone fractures, etc.

Abstract translation: 本发明涉及TGF- 通过向受试者施用结合TGF-β1b的抗体，从而增加骨生长，骨形成，骨量和骨强度的活性。 抗体的作用是增加成骨细胞数量和功能，同时降低破骨细胞数量和功能。 这些药物可用于治疗诸如骨质疏松症，佩吉特氏病，转移性骨癌，骨髓瘤骨病，骨折等疾病或病症。

公开(公告)号：US11192945B2

公开(公告)日：2021-12-07

申请号：US14582631

申请日：2014-12-24

Applicant: Vanderbilt University ,  Vanderbilt University

Inventor： James R. Edwards ,  Gregory R. Mundy

IPC: A61K39/395 ,  C07K16/22 ,  A61P19/08 ,  A61P19/10 ,  C07K16/24 ,  A61K39/00

Abstract: The invention regards the modulation of TGF-β activity by administering to a subject an antibody that binds to TGF-β, thereby increasing bone growth, bone formation, bone mass and bone strength. The antibody acts to increase osteoblast number and function while at the same time decreasing osteoclast number and function. Such drugs are useful in the treatment of diseases or disorders such as osteoporosis, Paget's disease, metastatic bone cancer, myeloma bone disease, bone fractures, etc.

公开(公告)号：US12233127B2

公开(公告)日：2025-02-25

申请号：US17270115

申请日：2019-08-22

Applicant: Vanderbilt University

Inventor： James E. Crowe, Jr.

IPC: A61K39/42 ,  A61P31/16 ,  C07K16/10 ,  G01N33/569 ,  A61K39/00

Abstract: The present disclosure is directed to antibodies binding previously undefined epitopes on influenza A virus hemagglutinin and methods for use thereof.

公开(公告)号：US12233051B2

公开(公告)日：2025-02-25

申请号：US18352721

申请日：2023-07-14

Applicant: VANDERBILT UNIVERSITY ,  The UAB Research Foundation ,  The United States of America, as Represented by the Secretary, Department of Health and Human Services

Inventor： Matthew Hall ,  Daniel J. Urban ,  John Knight ,  Ross Holmes ,  Kyle David Wood ,  Alex Waterson ,  Victor M. Darley-Usmar ,  Leonard M. Neckers

IPC: A61K31/427 ,  A61K31/4439 ,  A61K31/506

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

公开(公告)号：US20250051735A1

公开(公告)日：2025-02-13

申请号：US18720218

申请日：2022-12-22

Applicant: VANDERBILT UNIVERSITY ,  The United States of America, as Represented by The Secretary, Department of Health and Human Servic

Inventor： Matthew H. Wilson ,  Frederick Dyda ,  Alison B. Hickman ,  Wentian Lou

IPC: C12N9/12 ,  C12N15/62

Abstract: Disclosed herein is a modified transposase, comprising a core piggy Bac transposase having one or more modifications making it capable of excising and integrating a piggy Bac transposon in LE/LE configuration leading to hyperactivity. Also disclosed is a modified piggy Bac transposase capable of excising but not integrating a piggy Bac transposon in LE/LE configuration. Also disclosed herein is a modification of the mammalian Myotis lucifugus DNA transposon involving modification both its transposase and transposon LE and RE ends by truncations leading to hyperactivity.

公开(公告)号：US12216120B2

公开(公告)日：2025-02-04

申请号：US17655503

申请日：2022-03-18

Applicant: Vanderbilt University

Inventor： James E. Crowe, Jr. ,  Seth Zost ,  Robert Carnahan ,  Pavlo Gilchuk

IPC: C07K16/10 ,  A61P31/14 ,  G01N33/569 ,  A61K39/00

Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

公开(公告)号：US20250011790A1

公开(公告)日：2025-01-09

申请号：US18709175

申请日：2022-11-11

Applicant: Vanderbilt University ,  University of Tennessee Research Foundation

Inventor： Edward CHAUM ,  Sujoy BHATTACHARYA ,  Lawrence PFEFFER

IPC: C12N15/113

Abstract: Disclosed herein is a composition comprising a signal transducer and activator of transcription 3 (STAT3) inhibitor and one or more of a UNC51-like 1 (ULK1) inhibitor, histone deacetylase (HDAC) inhibitor, or an mTOR inhibitor in a pharmaceutically acceptable carrier. Also disclosed is a method for treating glioblastoma in a subject that involves administering to the subject an effective amount of a STAT3 inhibitor and one or more of a ULK inhibitor, an AMPKα inhibitor, an HDAC inhibitor, or an mTOR inhibitor.

公开(公告)号：US20250011320A1

公开(公告)日：2025-01-09

申请号：US18750829

申请日：2024-06-21

Applicant: Vanderbilt University

Inventor： Craig W. Lindsley ,  Darren W. Engers ,  Kayla J. Temple ,  Alison R. Gregro ,  Alexa E. Richardson ,  Madeline F. Long

IPC: C07D471/04 ,  A61K31/4545 ,  C07B59/00

Abstract: Deuterium-labeled 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidines substituted with pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.

公开(公告)号：US20250002485A1

公开(公告)日：2025-01-02

申请号：US18441380

申请日：2024-02-14

Applicant: Boehringer Ingelheim International GmbH ,  Vanderbilt University

Inventor： Jason ABBOTT ,  Joachim BROEKER ,  Jianwen CUI ,  Steve W. FESIK ,  Andreas GOLLNER ,  Tim HODGES ,  Jale KAROLYI-OEZGUER ,  Andrew LITTLE ,  Andreas MANTOULIDIS ,  Jason PHAN ,  Dhruba SARKAR ,  Christian Alan Paul SMETHURST ,  Qi SUN ,  Matthias TREU ,  Alex WATERSON

IPC: C07D413/14 ,  A61K31/506 ,  A61P35/00 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10

Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

公开(公告)号：US12178595B2

公开(公告)日：2024-12-31

申请号：US18377867

申请日：2023-10-09

Applicant: VANDERBILT UNIVERSITY

Inventor： Emmanuel A. Mannoh ,  Anita Mahadevan-Jansen

IPC: A61B5/00 ,  A61B34/20 ,  G01N21/64 ,  G01N21/65

Abstract: One aspect of the invention relates to a method for intraoperative detection of parathyroid gland viability in a surgery, comprising obtaining speckle contrast images of a parathyroid gland of a patent; and displaying the speckle contrast images of the parathyroid gland in real-time.